Can VOYXACT move beyond proteinuria? Otsuka’s two-year VISIONARY data may decide its FDA future
Otsuka will unveil two-year VISIONARY eGFR data for VOYXACT, a pivotal test of kidney preservation and its path to full FDA approval.
Pharma & Biotech
Pharma & Biotech
Otsuka reports VOYXACT preserved kidney function for two years in Phase 3 trial
Otsuka’s two-year VOYXACT data could reshape IgA nephropathy care. See what the eGFR results mean for FDA approval and clinical adoption.